Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
AtriCure to Announce Second Quarter 2025 Financial Results
08:00am, Tuesday, 08'th Jul 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
08:00am, Friday, 23'rd May 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
11:00am, Thursday, 15'th May 2025
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript
09:34pm, Tuesday, 29'th Apr 2025
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Ex
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
06:30pm, Tuesday, 29'th Apr 2025
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
06:10pm, Tuesday, 29'th Apr 2025
AtriCure (ATRC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.
AtriCure Reports First Quarter 2025 Financial Results
04:01pm, Tuesday, 29'th Apr 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure to Announce First Quarter 2025 Financial Results
08:00am, Tuesday, 08'th Apr 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Host Analyst & Investor Day on March 26, 2025
08:00am, Wednesday, 12'th Mar 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 13'th Feb 2025
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript
10:46pm, Wednesday, 12'th Feb 2025
AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Office
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
06:31pm, Wednesday, 12'th Feb 2025
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compa
AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates
06:16pm, Wednesday, 12'th Feb 2025
AtriCure (ATRC) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.21 per share a year ago.
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
04:01pm, Wednesday, 12'th Feb 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS
10:20am, Tuesday, 11'th Feb 2025
Besides Wall Street's top -and-bottom-line estimates for AtriCure (ATRC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the q
